The executive team and employees of Midatech represent a unique set of complementary competences, know-how and skill-sets in the life science industry. They have excellent senior executive track records in the global, pharmaceutical and biotech industry.
Dr Jim Phillips, MB., ChB., MBA.
Chief Executive Officer
Dr Phillips has a strong background in company leadership and business development. Jim Founded Talisker Pharma in 2004, which was the first and cornerstone acquisition of EUSA Pharma in 2006, as President Europe and Senior Vice President Corporate Development of EUSA Pharma Inc., Dr Phillips then led the strategy resulting in the acquisition of OPI and its ultimate acquisition by Jazz Pharmaceuticals in 2012. Jim has held a number of Board Directorships including Laurantis Pharma OY, Insense Ltd and until joining Midatech was Chairman of Prosonix Limited, guiding its successful transformation into a respiratory-focused business.
Dr Phillips initially held senior positions at Johnson & Johnson and Novartis Pharmaceuticals. At Novartis, Jim was in Clinical & Business Development, and was Board Director of the AGBHI $1.3bn business unit and a member of the company’s Clinical Leadership Team. He is a Physician by training.
Professor Thomas Rademacher, MD., PhD.
Chief Scientific Officer and Chairman
Professor Rademacher is a serial entrepreneur who has founded and led several successful biotechnology companies. Professor Rademacher has a Medical Degree and a PhD in biochemistry and is an inventor on over 50 patents. He is professor emeritus of molecular medicine at the University College London Medical School.
Justin Barry, BSc Hons., Mbiol., CBiol., QP.
Head GNP Design & Manufacture
Justin Barry is a biopharmaceutical industry executive with extensive experience in setting up and leading manufacturing and quality operations. Prior to joining Midatech, he led the Spanish operations for Genentech where he was first responsible for quality assurance and control and later set up a new manufacturing facility for Avastin®, one of the most successful biological drugs to date. Before that, Justin set up manufacturing facilities for the Wellcome foundation and GSK in Europe and the USA. At GSK, he also held executive positions in quality assurance and control.
Dr Jan Mous, PhD.
Chief Operating Officer
Dr Jan Mous is a biopharmaceutical industry executive who has led several successful biotechnology companies. Before joining Midatech, Dr. Mous was CEO of IntegraGen SA, a global biotech company based in France, which focused on next generation molecular diagnostics. Prior to that, he was CSO and executive board member of Lion Biosciences AG, co-leading the company in what was one of the most successful German biotech IPOs.
Dr Mous started his career in the biopharmaceutical industry at Hoffmann-La Roche where his last position was global head of Genomics and Proteomics. At Midatech, Dr Mous also chairs the Portfolio Management Board (PMB), which directs Midatech’s development projects.
Dr Stéphane Jallat, D Pharm., MEcon.
Chief Financial Officer
Dr Stéphane Jallat has broad experience in leading the finance operations of biotechnology companies. He was Finance Director of Piramed Ltd (2002-2009), a leader in the field of targeted cancer treatment. As a member of the senior management team, Dr Jallat played a major role in setting the strategic direction of the business and facilitating its subsequent acquisition by Hoffmann-La Roche in 2008.
Dr Jallat started his professional career at Arthur Andersen in 1991 before joining Rodaris Pharmaceuticals Ltd as Financial Controller in 1997. He qualified as a Doctor of Pharmacy and has a Masters degree in Economics from ESSEC, one of the two leading business schools in France.
Storme Moore-Thornicroft, MBA.
Vice President, Corporate Management
Storme Moore-Thornicroft is a co-founder of Midatech Ltd. She is an Executive Director and Company Secretary and sits on the boards of subsidiaries Midatech Biogune S.L. and Midatech Andalucia S.L.. She was instrumental in the formation of Midatech’s subsidiaries (Spain, Switzerland) and two joint venture entities (USA). She has over 15 years of biotech industry experience and has held senior positions in several biotech companies where she assisted in their formations, raised grants and equity capital and led organizational development activities. Previously, Storme developed significant experience in the management of intellectual property and technology transfer at University College London.